← boardnext 2030-02
KROS
Keros Therapeutics, Inc.distress 2/10 · well-funded / low risk$9.96-2%today-54% from 52w high
Hematology 1Respiratory 1
Lead: NASH With Fibrosis · est. market ~$5B (approx, global)
Revenue
pre-revenue
Liquidity
$281M
Runway
4.9 yrs
Shares 1y
-51%
Price & events
-48.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.4%
1D
-6.1%
1W
-9.5%
1M
-13.8%
3M
-48.1%
6M
-31.0%
1Y
-80.4%
2Y
-73.6%
5Y
-85.7%
All
Overview
- Market Cap
- $197.13M
- Volume
- 25.11K
- 52 Week Range
- $9.91 – $21.84
- Total Shares
- 19.79M
- Float Shares
- 17.80M
- Short %
- 5.97%
- % Held by Insiders
- 3.71%
- % Held by Institutions
- 95.12%
- RVOL
- 0.09x
- Beta
- 0.97
Pipeline stages · 3 programs
Efruxifermin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
KER-047
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Dose A KER-012, Dose B KER-012, Dose C KER-012
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2030-02 Estimated 50% readout ~2030-04-17 | Phase 3 | Efruxifermin | NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis | — | recruiting |
| 2033-02 Estimated 50% readout ~2033-04-17 | Phase 3 | Efruxifermin | NASH With Fibrosis, MASH With Fibrosis | — | recruiting |
| 2025-08-29 | Phase 2 | KER-047orphan | Iron Deficiency Anemia | 0 | withdrawn |
| 2025-03-05 | Phase 2 | Dose A KER-012, Dose B KER-012, Dose C KER-012 | Pulmonary Arterial Hypertension | 113 | completed |
Catalyst news & presentations · 12
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- June 8, 2026 at 4:00 p.m. Eastern timeconferencedata presentationsecondaryfireside chat presentation at Goldman Sachs 47th Annual Global Healthcare ConferenceSEC 8-K
- Tuesday, March 10, 2026 at 1:00 p.m. Eastern timeconferencedata presentationsecondaryFireside chat presentation at Leerink Partners Global Healthcare ConferenceSEC 8-K
- 2026-03-09partnershiprinvatercept · Agreement with Massachusetts General Hospital to design Phase 2 trial in ALSSEC 8-K
- Tuesday, March 3, 2026 at 9:50 a.m. Eastern timeconferencedata presentationsecondaryFireside chat presentation at TD Cowen 46th Annual Health Care ConferenceSEC 8-K
- Wednesday, February 25, 2026 at 11:20 a.m. Eastern timeconferencedata presentationsecondaryCorporate presentation at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceSEC 8-K
- September 9, 2025 at 12:00 p.m. Eastern timeconferencedata presentationsecondaryCorporate presentation at H.C. Wainwright 27th Annual Global Investment ConferenceSEC 8-K
- September 6, 2025conferencedata presentationsecondaryPhase 1KER-065 · Additional clinical data from Phase 1 trial presented at ASBMR 2025 Annual MeetingSEC 8-K
- September 4, 2025 at 2:15 p.m. Eastern timeconferencedata presentationsecondaryFireside chat at 2025 Wells Fargo Healthcare ConferenceSEC 8-K
- July 17, 2025trial initiationsecondaryPhase 3elritercept · First patient dosed in Phase 3 RENEW clinical trial of elriterceptSEC 8-K
- 2024-12-12safety signalcibotercept · Voluntary halt of dosing in 3.0 mg/kg and 4.5 mg/kg arms of TROPOS trial due to pericardial effusion adverse eventsSEC 8-K
- 2024-12-03partnershipelritercept · Exclusive license agreement with Takeda for global rights excluding China, Hong Kong, Macau; $200M upfront and up to $1.11B milestones.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-03-05Wells FargoOverweight
- 2025-11-28B of A SecuritiesNeutral
- 2025-11-12OppenheimerOutperform
- 2025-11-11Wells FargoOverweight
- 2025-11-06WedbushNeutral
- 2025-08-08HC Wainwright & Co.Buy
Competitors — NASH With Fibrosis
- none identified
Recent news
- 2026-07-22Keros Therapeutics Announces CFO Resignation and Interim Successor - TipRanks
- 2026-07-22Keros Therapeutics (NASDAQ: KROS) names interim finance and accounting head - Stock Titan
- 2026-07-22Discipline and Rules-Based Execution in KROS Response - Stock Traders Daily
- 2026-07-20KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - qz.com
- 2026-07-20KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment - qz.com
- 2026-07-17BlackRock Portfolio Management (KROS) discloses 5.7% ownership in Keros Therapeutics - Stock Titan
- 2026-07-17Insiders Sold Keros Therapeutics Prematurely At US$15.15 With Stock Trading Higher - simplywall.st
- 2026-07-16Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.